Introduction
DNA-based immunization is a rapidly expanding area of vaccine research and development and is also being considered for cancer immunotherapy. 1, 2 Particle-mediated gene transfer of nonviral expression plasmids into the skin using the gene gun, [3] [4] [5] as well as immunizations with recombinant viral vectors 6, 7 lead to the induction of potent Ag-specific cellular and humoral immune responses. In a variety of experimental model tumor Ag systems, the responses elicited by either gene delivery system have been shown to protect mice from normally lethal challenges with antigen-expressing tumor cell lines. Nonviral plasmid DNA-based immunizations, however, have several clinically relevant advantages over strategies employing recombinant viral vectors. First, they permit the gene(s) of interests to be transcribed without immunological interference from viral vector proteins. This is of particular importance since the application of recombinant adenoviruses for immunization appears to be limited by the induction of neutralizing antibodies to viral envelope proteins. Second, they easily permit the simultaneous transfer of several genes, thereby allowing co-delivery of genes encoding Ag in combination with genes encoding immunostimulatory molecules, such as cytokines, which may modulate the resulting immune response towards a desired phenotype. Third, their use avoids the risk of recombination, which is associated with replication-defective viral vectors, while the transient nature of plasmid DNA gene transfer minimizes the possibility of insertion of foreign DNA into the genome. Lastly, large quantities of stable and highly pure plasmid DNA can be readily made available for vaccine production. 8 It has recently been recognized that gene gun immuni-zation promotes a predominate Th2-associated immune response. 9, 10 However, a powerful Th1-and CTLmediated response with production of IFN-␥ is thought to be necessary for the induction of antitumor immunity. 11 Whereas the two types of responses should be distinguishable based on the relative intensities of the cellular immune reactivity they induce, the strong immunogenicity of the foreign Ag used in the model studies tends to obscure these differences. They can be distinguished, however, on the basis of the isotype profile of the Ag-specific antibodies involved in the responses. In mice, production of ␥1 antibodies is associated with Th2-mediated immune responses, while the predominate antibody isotype produced in a Th1-associated response is ␥2␣. The isotype profile difference can be attributed, in part, to the immunomodulatory activities of Th1-associated cytokines, such as IFN-␣ and IFN-␥, which are required for isotype switching and production of IgG 2a molecules. 12, 13 In an approach for optimizing the efficacy of tumor Ag vaccines delivered by gene gun immunization, we initiated a study to characterize the immune responses induced with a non-viral plasmid encoding a model vaccine Ag, ␤-galactosidase (␤gal), alone or in conjunction with genes encoding IFN-␣ or IL-12. In particular, we analyzed the isotype profiles of the Ag-specific antibodies induced by the different types of gene gun immunizations in order to determine the overall Th1/Th2 bias of the immune responses. For comparison, we investigated the type of immune response elicited by intradermal injections of a corresponding vaccine employing a recombinant adenovirus as the vector. The results from these experiments were then successfully applied to gene gun immunization targeting a tumor Ag system considerably less immunogenic in mice than ␤gal, the tumor-specific p53 mutant Ag expressed by the chemically induced BALB/c Meth A sarcoma.
Results
Gene gun immunization with plasmid DNA encoding ␤gal leads to cutaneous Ag expression and the induction of potent and long-lasting specific cellular immune responses The expression of the ␤gal experimental Ag following gene gun immunization of the skin was verified by histochemical analysis of skin biopsies. Strong ␤gal activity could be detected in skin harvested 36 h following particle-mediated gene transfer with the plasmid pCI-␤gal. In contrast, no ␤gal activity was found after gene gun bombardment with the plasmid pCI-EGFP, which encodes enhanced green fluorescent protein (EGFP). Confirmation of the induction of antigen-specific cellular immune responses following gene gun immunization was then sought. Splenocytes harvested from mice immunized with pCI-␤gal and restimulated in vitro with the ␤gal 876-884 peptide displayed strong cytolytic activity against ␤gal 876-884 -pulsed C26 but not against unpulsed C26 target cells (Figure 1 ). CTL assays with splenocytes harvested from mice immunized with the vector control (pCI) and restimulated with the ␤gal 876-884 peptide only resulted in background levels of reactivity against the various target cells. The cytolytic reactivity generated from splenocytes obtained from pCI-␤gal-immunized mice against ␤gal-pulsed C26 target cells was blocked by anti-CD8 mAb, but not by anti-CD4 mAb, suggesting that the effectors were CD8 + , MHC class I-restricted CTL (data not shown).
The induction of ␤gal-specific CD4 + , MHC class IIrestricted T cells following gene gun immunization was also studied. It was determined that splenocytes harvested from pCI-␤gal-immunized mice, but not controlimmunized mice, strongly proliferated and released IFN-␥ in response to in vitro restimulation with r␤gal ( Figure  2 ). Proliferation and cytokine release could be blocked by anti-CD4 or anti-Ia (MHC class II) mAb, but not by anti-CD8 mAb, suggesting that the observed responses were mediated by CD4 + , MHC class II-restricted Th cells. Importantly, we could detect ␤gal-specific CTL and Th cell responses for as long as 9 months after gene gun immunizations. 
Antibody blocking of proliferation and cytokine release was performed by addition of the indicated hybridoma supernatants (final dilution of 1:5). Results of a representative experiment are presented as mean cpm (a) and mean pg/ml IFN-␥ (b) of triplicate determinations (± s.e.m.).
Intradermal injection of recombinant adenovirus induces similar levels of cellular immunity as gene gun immunization with nonviral plasmid DNA A major goal of our study was to compare the immune responses induced by gene gun immunization using plasmid DNA with those induced by intradermal injection of a recombinant adenoviral vector. In vitro restimulation of splenocytes harvested from AdCMV-␤gal-immunized mice with the ␤gal 876-884 peptide resulted in the generation of effectors with strong cytolytic reactivities against ␤gal 876-884 -pulsed, but not against unpulsed C26 target cells. No reactivity could be detected in splenocytes from AdCMV-EGFP-immunized mice. As shown in Figure 3 , the levels of cytolytic reactivity were similar to those induced by gene gun immunization. Splenocytes harvested from AdCMV-␤gal-immunized mice also displayed a strong proliferative response associated with IFN-␥ release when in vitro restimulated with r␤gal. Again, as shown in Figure 4 , these responses were comparable to those of splenocytes obtained from gene gunimmunized mice, and they could be blocked by anti-CD4 or anti-Ia (MHC class II) mAb, but not by anti-CD8 mAb.
The isotype profile of the anti-␤gal antibody response induced by gene gun immunization with pCI-␤gal differs from that induced by intradermal injection of recombinant AdCMV-␤gal An isotype-specific anti-␤gal antibody ELISA was established in order to evaluate the Th bias of the Ag-specific humoral immune responses induced by the two immunization systems being studied. Serum samples were obtained from groups of mice 1, 3, 6 and (in a few groups) 9 months after the initial immunization. Strong ␤gal-specific antibody responses were detectable after 1 month and persisted without significant decrease for at least 6-9 months in all animals gene gun-immunized with pCI-␤gal or intradermally injected with AdCMV␤gal, but not in any of the control-immunized animals (data not shown). As illustrated in Figure 5 , gene gun immunizations resulted in the predominant production of anti-␤gal ␥ 1 antibodies with considerable, albeit lower levels of ␥ 2a antibodies. Intradermal injections with AdCMV-␤gal, in contrast, resulted in the almost exclusive production of ␥ 2a antibodies with little production of ␥ 1 antibodies.
Co-delivery of plasmid DNA expressing IFN-␣ or IL-12 enhances the production of anti-␤gal ␥ 2a antibodies following gene gun immunization with pCI-␤gal The Th1-biasing cytokines IFN-␣ and IL-12 are produced in large amounts during the early phase of viral infections. Since IFN-␣ and IFN-␥ (which is induced by IL-12) are associated with isotype-switching and production of ␥ 2a antibodies in mice, we hypothesized that these cytokines are induced following intradermal injection of recombinant adenovirus and play a crucial role in determining the isotype profile of humoral responses they induce. In an attempt to mimic an adenovirus infection with nonviral plasmid DNA delivered by gene gun immunization, we co-delivered plasmid DNA expressing IFN-␣ or IL-12 along with plasmid DNA expressing ␤gal. As shown in Figure 6 , this resulted in the enhanced production of ␤gal-specific ␥ 2a antibodies. This indicates a shift toward a Th1-biased immune response.
Co-delivery of plasmid DNA expressing IL-12 and plasmid DNA expressing the p53 tumor Ag is required for the induction of an effective anti-tumor immunity in the BALB/c Meth A tumor model We next investigated the potential of DNA immunization in a well-characterized murine tumor model, the chemically induced Meth A sarcoma. Meth A sarcoma expresses a p53 missense mutation at codon 234, which occurs in an epitope, p53 [232] [233] [234] [235] [236] [237] [238] [239] [240] , that can be presented on the cell surface in association with H-2K d molecules. This epitope has been shown to be capable of being recognized by CTL and inducing tumor rejection. 14, 15 The plasmid pCI-p53 mut7/8 expressing exon 7 and 8 (codons 225-285) of a mutant p53 derived from the Meth A sarcoma and the missense mutation at codon 234, was constructed as a DNA vaccine targeting this tumor-specific Ag. In the tumor protection setting, which has been shown critically to be dependent on induction of a Th1-biased immune response, we observed that co-delivery of plasmid DNA encoding IL-12 along with pCI-p53 mut7/8 was required for the induction of tumor rejection activity (Figure 7) . Whereas three out of five animals immunized with pCIp53 mut7/8 + pCMV-dIL12 ultimately rejected the Meth A challenge, administration of pCI-p53 mut7/8 alone had no significant effect on inhibiting tumor growth. These results are consistent with the ability of IL-12 to enhance a Th1-biased immune response following gene gun immunization.
Discussion
Various gene transfer systems are currently being considered for the implementation of DNA-based immunization. In the study presented here, we employed the ␤gal model tumor Ag system to compare characteristics of the antigen-specific immune response induced by nonviral plasmid DNA immunization using the gene gun with those of the response induced by intradermal injection of a recombinant adenoviral vector encoding the antigen. Our results indicate that both gene transfer systems elicit potent CD8 + and CD4 + T cell-mediated anti␤gal responses. Immunization with either the plasmid pCI-␤gal or the recombinant adenovirus AdCMV-␤gal leads to the induction of potent CD8 + CTL recognizing the known ␤gal-derived epitope, ␤gal 876-884 , as well as strong ␤gal-specific proliferation and cytokine production by CD4 + Th cells. The isotype profiles of ␤gal-specific antibody responses induced by the two gene transfer systems, however, were distinct from each other. Gene gun immunization promoted the predominant production of antibodies of anti␤gal ␥ 1 antibodies, which is characteristic of a Th2-associated response, while immunization with the recombinant adenovirus almost exclusively promoted the production of anti-␤gal ␥ 2a antibodies, a Th1-associated isotype. The observation that gene gun immunizations of mice appear to induce immune responses with a Th2 bias, characterized by the expansion of IL-4-producing CD4 + T cells and the production of ␥ 1 antibodies has been described by several groups. 9, 10 Interestingly, intradermal injections of plasmid DNA in saline have been found to induce preferentially a Th1 bias of the immune response in mice. 10, 16 The injection of large amounts of plasmid DNA has been shown to induce the production of proinflammatory Th1-associated cytokines such as IFN-␣, TNF-␣, IL-6, and IL-12 via specific immunostimulatory DNA sequences present in plasmid DNA of bacterial origin. 17, 18 This might explain the Th1-biased immune responses following intradermal injections of plasmid DNA in saline, since it requires up to 100 times more DNA than gene gun immunization. Intradermal injection of recombinant adenoviral vectors most likely also pro- The results of our experiments show that co-delivery of plasmids expressing IFN-␣ or IL-12 along with pCI␤gal using the gene gun increases the production of ␤gal-specific ␥ 2a antibodies, thus mimicking the Th1-biased immune responses associated with an adenoviral infection. Other investigators have reported increased cellular immune responses, which are characteristic of Th1-biased immune responses, following co-delivery of IL-12 along with antigen-encoding cDNA. [19] [20] [21] Importantly, our experiments using the Meth A tumor model, clearly demonstrate that the induction of effective antitumor immunity by gene gun immunization with plasmid DNA encoding the p53 tumor Ag, which is considerably less immunogenic than ␤gal, appears to profit from co-delivery of plasmid DNA encoding the Th1-biasing cytokine IL-12.
Taken together, these results indicate that one can enhance the potential of inducing effective antitumor immune responses when using gene gun immunization with nonviral plasmid DNA by co-delivery of genes encoding Th1-biasing cytokines. Our findings concerning IL-12-mediated enhancement of antitumor immune responses are in concert with those of studies involving conventional immunizations of mice with tumor-specific peptide-based vaccines, including the Meth A p53 mutant Ag. Using either the tumor-specific Meth A p53 mutant epitope 22 or the CMS5 MAP kinase mutant epitope, 23 the co-administration of recombinant IL-12 was shown to be essential for induction of effective antitumor immunity.
Materials and methods
Mice, cell lines and antibodies Female BALB/c mice, 6-10 weeks old, were obtained from Jackson Laboratories (Bar Harbor, ME, USA), and maintained in a specific pathogen-free facility (Central Animal Facility, University of Pittsburgh). C26 is a chemically induced BALB/c murine adenocarcinoma. 24 Hybridomas producing anti-CD4 (clone L3T4, TIB207), anti-CD8 (clone GK1.5, TIB210) and anti-Ia (MHC class II; clone M5/114, TIB120) mAb were obtained from the American Type Culture Collection (Rockville, MD, USA). These supernatants contained approximately 5 g mAb/ml. These cell lines were maintained in complete medium (CM) consisting of RPMI 1640 supplemented with 10% heat-inactivated FBS, 2 mm l-glutamine, 1 mm sodium pyruvate, 0.1 mm nonessential amino acids, 0.1 mm Hepes, 50 m 2-ME, 100 IU/ml penicillin and 100 g/ml streptomycin. All cell culture reagents were purchased from Gibco-BRL (Gaithersburg, MD, USA). Meth A is a chemically induced BALB/c sarcoma. 25 It carries a p53 missense mutation at codon 234, which generates a tumor-specific peptide epitope, p53 232-240 , capable of being presented to CTL by H-2K d molecules.
14,15
Plasmids, recombinant adenovirus and peptides The plasmids pCI-␤gal and pCI-EGFP were constructed by inserting fragments containing the E. coli ␤gal gene (kindly provided by Auragen/Powderject, Madison, WI, USA) or the EGFP gene (Clontech, Palo Alto, CA, USA) into the expression vector pCI (Promega, Madison, WI, USA). The construction of pCMV-A-mIFN␣2 containing the murine IFN-␣2 gene has been described. 26 The plasmid pWRG3169 (here designated as pCMV-mIL12) containing coding sequences for the p35 and p40 subunits of murine IL-12 driven by tandem CMV promoters has been described 27 and was kindly provided by Auragen/ Powderject. The plasmid pCI-p53 mut7/8 was constructed by subcloning bp 675 to 855 (corresponding to codons 225-285) of the Meth A p53 cDNA (kindly provided by M Oren, Weizmann Institute, Rehovot, Israel) into the expression plasmid pCI using PCR techniques including the generation of an artificial start and stop codon to allow for translation of the resulting minigene. The insert was sequenced in both directions to exclude mutations introduced by PCR. Plasmids were grown in E. coli strain DH5␣ and purified using Qiagen Endofree Plasmid Maxi Kits (Qiagen, Chatsworth, CA, USA). The recombinant adenoviruses AdCMV-␤gal and AdCMV-EGFP were propagated on 293 and Cre8 cells, respectively, and purified by cesium chloride gradient centrifugation according to standard protocols. 28 The H-2L d -binding ␤gal-encoded peptide, TPHPARIGL (␤gal 876-884 ) was synthesized by standard F-moc chemistry and purified by HPLC in the Peptide Synthesis Facility of the University of Pittsburgh Cancer Institute (shared resource). Detection of ␤gal in particle-bombarded skin Mice were killed 36 h following particle-mediated gene transfer to their skin. Bombarded skin was harvested, snap frozen in liquid nitrogen, and stored at −80°C. Cryosections were fixed in 0.5% glutaraldehyde, stained for ␤gal expression with X-gal (5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside; Sigma Chemical), counterstained with hematoxylin and analyzed.
Immunization of mice

CTL assays
Splenocytes from immunized mice or from non-immunized littermates were harvested and pooled at various time-points after immunization. Twenty-four-well plates were used for restimulations (at 37°C in 5% CO 2 -humidified air) with 4 × 10 6 cells resuspended in 2 ml of CM containing 1 g/ml ␤gal 876-884 peptide and 25 IU/ml recombinant human IL-2 (Chiron, Emeryville, CA, USA) per well. After 5 days, lymphocytes were tested for their cytolytic reactivity against C26 and ␤gal 876-884 -pulsed C26 target cells in triplicate in standard 4 h 51 Cr release assays using 96-well round-bottom plates. Target cells (2 × 10 6 ) were radiolabeled with 100 Ci Na 2
51
CrO 4 (NEN-Dupont, Bedford, MA, USA) for 1 h at 37°C. Peptide-pulsed targets were prepared by the addition of 1 g/ml peptide during radiolabeling. Hybridoma supernatants containing anti-CD4 and anti-CD8 mAb were used at a final dilution of 1:5 for blocking experiments. Maximum and spontaneous, as well as the percentage of specific 51 Cr release, were determined by standard procedures.
Proliferation and cytokine release assays Splenocytes obtained from immunized mice and nonimmunized littermates at various time-points after immunization were tested for their responses to r␤gal (Sigma Chemical). Splenocytes at cell densities of 10 5 and 10 6 per well/0.2 ml CM were restimulated in triplicate in 96-well plates in the presence of 20 g/ml r␤gal to determine antigen-specific proliferation and cytokine production, respectively. Hybridoma supernatants containing anti-CD4, anti-CD8 and anti-Ia mAb were used at a final dilution of 1:5 for blocking experiments. Proliferation was assessed at the end of 5 days by adding 3 HdThd (NEN-Dupont) for the final 18 h (1 Ci per well). Cells were harvested on to glass fiber mats using a multiple cell harvester and the degree of thymidine incorporation was determined in a liquid scintillation counter. Murine IFN-␥ in supernatants harvested after 48 or 72 h culture was determined in an ELISA using purified rat anti-mouse IFN-␥ (clone R4-6A2; Pharmingen) at a concentration of 2 g/ml as the capture antibody and biotinylated rat anti-mouse IFN-␥ (clone XMG1.2; Pharmingen) at a concentration of 1 g/ml as the detection antibody, followed by incubation with peroxidase-conjugated streptavidin (Boehringer Mannheim, Indianapolis, IN, USA) at a 1:20 000 dilution. Color development and analysis were performed as described below for antibody measurements. The detection limit of this assay was 50 pg/ml of mIFN-␥ (Pharmingen).
Antibody measurements
Anti-␤gal antibodies present in serum samples obtained from mice at various time-points after their immunization were measured by ELISA using r␤gal as a solidphase Ag. Briefly, microtiter plates were coated with 5 g/ml r␤gal in carbonate buffer (pH 9.6) for 16 h at 4°C and blocked with PBS containing 3% BSA and 0.05% Tween. Serum samples were serially diluted in PBS containing 1% BSA and 0.05% Tween (assay buffer) and added for 1 h. Bound antibodies of the ␥ 1 and ␥ 2a isotypes were detected using isotype-specific goat anti-mouse Ab (Sigma Chemical) at a 1:10 000 dilution in assay buffer followed by peroxidase-conjugated donkey anti-goat Ab (Jackson Research Laboratories) at a 1:20 000 dilution in assay buffer and color development with TMB Peroxidase Substrate System (Kirkegaard and Perry, Gaithersburg, MD, USA). Reactions were stopped by the addition of 1 n H 2 SO 4 .
Tumor rejection assay Groups of five BALB/cJ female mice were immunized twice by gene gun with pCI vector control alone, pCIp53 mut7/8 alone, pCI vector control + pCMV-dIL12, or pCIp53 mut7/8 + pCMV-dIL12. Two weeks after their second immunization, the mice were challenged bilaterally, with 1 × 10 5 in vivo grown Meth A cells injected subcutaneously. Tumor growth was monitored twice weekly using a vernier caliper and recorded as mean tumor diameter (mm).
Statistical analysis
Fisher's exact method or the Student's t test were performed to interpret the differences between experimental groups presented as mean tumor diameter, mm ± mean standard error (m.t.d. ± m.s.e.). Significance at 95% confidence limits was calculated for individual experiments.
